The earnings call highlighted strong revenue and procedure growth, successful product launches, and robust financial performance. However, challenges in international markets, tariff impacts, and supply constraints were noted as significant issues.

Company Guidance -

Q3 2025

In the recent earnings call, Intuitive provided comprehensive guidance for the remainder of 2025. They revised their da Vinci procedure growth forecast to be between 15.5% and 17%, reflecting robust procedure performance and capital placements. The company reported a 21% revenue growth, with significant contributions from the U.S., where da Vinci 5 systems saw a strong launch. They placed 395 da Vinci systems, including 180 da Vinci 5 systems, and 54 Ion systems during the quarter. System utilization increased by 2% overall, with notable growth in SP and Ion platforms at 30% and 8%, respectively. Their financial outlook includes a pro forma gross margin expectation of 66% to 67% of revenue, with operating expense growth projected between 10% and 14%. Intuitive also highlighted recent FDA approval for their curved vessel sealer, enhancing their advanced energy instrument portfolio, and received clearance for tracheal bronchoplasty procedures, underscoring their commitment to innovation and improved patient outcomes.

Strong Revenue Growth

Revenue growth was 21% year-over-year, driven by solid procedure performance and capital placements.

Procedure and System Utilization Increases

Da Vinci procedure growth in the quarter was 17%, with regional performance highlights in India, Korea, and distribution markets. System utilization for multiport platforms grew 2% year-over-year, with SP and Ion increasing by 30% and 8% respectively.

New Product Launches and Clearances

Da Vinci 5 is in broad launch in the U.S. and received clearances in Europe and Japan. The vessel sealer curved received 510(k) clearance, and procedures for tracheal bronchoplasty were also cleared.

SP and Ion Segment Growth

SP procedure growth was strong at 88% year-over-year, with significant growth in Korea. Ion procedures grew 52% to approximately 35,000 in the quarter.

Strong Financial Performance

Pro forma operating margin was 39% and pro forma earnings per share increased by 23%.

Intuitive Surgical (ISRG) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ISRG Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 16, 2025	2025 (Q3)	1.99 / -	1.84	―	―	―
Jul 22, 2025	2025 (Q2)	1.93 / 2.19	1.78	23.03% (+0.41)	―
Apr 22, 2025	2025 (Q1)	1.74 / 1.81	1.5	20.67% (+0.31)
Jan 23, 2025	2024 (Q4)	1.79 / 2.21	1.6	38.12% (+0.61)	―
Oct 17, 2024	2024 (Q3)	1.64 / 1.84	1.46	26.03% (+0.38)
Jul 18, 2024	2024 (Q2)	1.54 / 1.78	1.42	25.35% (+0.36)
Apr 18, 2024	2024 (Q1)	1.42 / 1.50	1.23	21.95% (+0.27)	―
Jan 23, 2024	2023 (Q4)	1.48 / 1.60	1.23	30.08% (+0.37)	―
Oct 19, 2023	2023 (Q3)	1.42 / 1.46	1.19	22.69% (+0.27)	―
Jul 20, 2023	2023 (Q2)	1.33 / 1.42	1.14	24.56% (+0.28)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ISRG Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 22, 2025	$511.00	$501.95	-1.77%
Apr 22, 2025	$478.74	$487.93	+1.92%
Jan 23, 2025	$608.66	$584.05	-4.04%
Oct 17, 2024	$473.73	$521.15	+10.01%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.